Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
Daniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Cancer Science
|
November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
Takayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
The Lancet. Oncology
|
April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde, Marina Pulido, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Journal of the National Cancer Institute
|
August 25, 2020
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database
Anna D Wagner, Axel Grothey, Thierry Andre, et al.
Journal of the National Cancer Institute
|
June 1, 2021
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer
Jun Yin, Romain Cohen, Zhaohui Jin, et al.
The Lancet. Oncology
|
August 8, 2024
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study
Kazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
Giovanni Fucà, Romain Cohen, Sara Lonardi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
Daniel J Sargent, Harry S Wieand, Daniel G Haller, et al.
Cancer Science
|
November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
Takayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
The Lancet. Oncology
|
April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
Thierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde, Marina Pulido, Isabelle Ray-Coquard, et al.
The New England Journal of Medicine
|
March 29, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey, Alberto F Sobrero, Anthony F Shields, et al.
Journal of the National Cancer Institute
|
August 25, 2020
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database
Anna D Wagner, Axel Grothey, Thierry Andre, et al.
Journal of the National Cancer Institute
|
June 1, 2021
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer
Jun Yin, Romain Cohen, Zhaohui Jin, et al.
The Lancet. Oncology
|
August 8, 2024
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 7, 2025
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study
Kazumasa Yamamoto, Hideaki Bando, Toshihiro Misumi, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
Giovanni Fucà, Romain Cohen, Sara Lonardi, et al.
Page
of 6